Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis
1
조회
0
다운로드
2
인용
0
참고문헌
초록
Epigenetic alterations, especially histone methylation, are key factors in cell migration and invasion in cancer metastasis. However, in lung cancer metastasis, the mechanism by which histone methylation regulates metastasis has not been fully elucidated. Here, we found that the histone methyltransferase SMYD2 is overexpressed in lung cancer and that knockdown of SMYD2 could reduce the rates of cell migration and invasion in lung cancer cell lines via direct downregulation of SMAD3 via SMYD2-mediated epigenetic regulation. Furthermore, using an in vitro epithelial-mesenchymal transition (EMT) system with a Transwell system, we generated highly invasive H1299 (In-H1299) cell lines and observed the suppression of metastatic features by SMYD2 knockdown. Finally, two types of in vivo studies revealed that the formation of metastatic tumors by shSMYD2 was significantly suppressed. Thus, we suggest that SMYD2 is a potential metastasis regulator and that the development of SMYD2-specific inhibitors may help to increase the efficacy of lung cancer treatment.
Abstract
Epigenetic alterations, especially histone methylation, are key factors in cell migration and invasion in cancer metastasis. However, in lung cancer metastasis, the mechanism by which histone methylation regulates metastasis has not been fully elucidated. Here, we found that the histone methyltransferase SMYD2 is overexpressed in lung cancer and that knockdown of SMYD2 could reduce the rates of cell migration and invasion in lung cancer cell lines via direct downregulation of SMAD3 via SMYD2-mediated epigenetic regulation. Furthermore, using an in vitro epithelial-mesenchymal transition (EMT) system with a Transwell system, we generated highly invasive H1299 (In-H1299) cell lines and observed the suppression of metastatic features by SMYD2 knockdown. Finally, two types of in vivo studies revealed that the formation of metastatic tumors by shSMYD2 was significantly suppressed. Thus, we suggest that SMYD2 is a potential metastasis regulator and that the development of SMYD2-specific inhibitors may help to increase the efficacy of lung cancer treatment.
참고문헌 (41)
- Chen, H. H., "Circular RNAs in lung cancer: recent advances and future perspectives", Front. Oncol, 11, pp.664290~ (2021)
- Yin, L., "The role of exosomes in lung cancer metastasis and clinical applications : an updated review", J. Transl. Med, 19, pp.312~ (2021)
- Zhang, T., "The interplay of histone modifications-writers that read", EMBO Rep, 16, pp.1467~1481 (2015)
- Bhat, K. P., "Epigenetics and beyond : targeting writers of protein lysine methylation to treat disease", Nat. Rev. Drug Discov, 20, pp.265~286 (2021)
- Kim, K., "RNA-seq based transcriptome analysis of EHMT2 functions in breast cancer", Biochem. Biophys. Res. Commun, 524, pp.672~676 (2020)
- Lee, J., "EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression", Mol. Oncol, 15, pp.2989~3002 (2021)
- Ryu, T. Y., "Human gut-microbiome-derived propionate coordinates proteasomal degradation via HECTD2 upregulation to target EHMT2 in colorectal cancer", ISME J, 16, pp.1205~1221 (2022)
- 류태영, "SETDB1 regulates SMAD7 expression for breast cancer metastasis", BMB Reports, 52(2), pp.139~144 (2019), 생화학분자생물학회[DOI]
- Li, L. X., "Cross-talk between CDK4", 6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis, 2020, pp.6, eabb3154~
- Shang, L., "Inhibition of SMYD2 sensitized cisplatin to resistant cells in NSCLC through activating p53 pathway", Front. Oncol, 9, pp.306~ (2019)
- Wang, Y., "SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer", Exp. Cell Res, 404, pp.112649~ (2021)
- Kojima, M., "The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells", Oncol. Lett, 20, pp.153~ (2020)
- Lai, Y., "SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer", Mol. Cell. Biochem, 477, pp.2149~2159 (2020)
- Yu, Y. Q., "SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth", Cell Death Dis, 13, pp.52~ (2022)
- Ji, Y., "SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1", Cell Death Discov, 8, pp.274~ (2022)
- Meng, F., "SMYD2 suppresses APC2 expression to activate the Wnt", betacatenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer, 2020, pp.10, 997~1011
- Cho, H. S., "RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation", Neoplasia, 14, pp.476~486 (2012)
- Deng, X., "Critical roles of SMYD2-mediated beta-catenin methylation for nuclear translocation and activation of Wnt signaling", Oncotarget, 8, pp.55837~55847 (2017)
- Hamamoto, R., "Critical roles of non-histone protein lysine methylation in human tumorigenesis", Nat. Rev. Cancer, 15, pp.110~124 (2015)
- Wang, R., "Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells", Cancer Sci, 108, pp.1203~1209 (2017)
- Wang, X., "Harnessing carcinoma cell plasticity mediated by TGF-beta signaling", Cancers (Basel), 13, pp.3397~ (2021)
- Hu, Y., "Tartrate-resistant acid phosphatase 5", ACP5 interacts with p53 to control the expression of SMAD3 in lung adenocarcinoma, 2020, pp.16, 272~288
- Tang, Y. N., "Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis", Nat. Commun, 6, pp.8230~ (2015)
- Guo, S., "Inhibition mechanism of lung cancer cell metastasis through targeted regulation of Smad3 by miR-15a", Oncol. Lett, 19, pp.1516~1522 (2020)
- Zhang, J. X., "MicroRNA-32-5p inhibits epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting SMAD family 3", J. Cancer, 12, pp.2258~2267 (2021)
- Lee, M. O., "Development of a quantitative prediction algorithm for target organ-specific similarity of human pluripotent stem cell-derived organoids and cells", Nat. Commun, 12, pp.4492~ (2021)
- Lee, E. S., "Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression", Clin. Cancer Res, 14, pp.7397~7404 (2008)
- Nguyen, D. X., "WNT", TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis, 2009, pp.138, 51~62
- Huang, H., "Matrix Metalloproteinase-9(MMP-9)as a cancer biomarker and MMP-9biosensors : recent advances", Sensors(Basel), 18, pp.3249~ (2018)
- Mehner, C., "Tumor cell-produced matrix metalloproteinase 9(MMP-9)drives malignant progression and metastasis of basal-like triple negative breast cancer", Oncotarget, 5, pp.2736~2749 (2014)
- Owyong, M., "MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy", Life Sci. Alliance, 2, pp.e201800226~ (2019)
- Yi, X, "Histone methyltransferase SMYD2: ubiquitous regulator of disease", Clin. Epigenetics, 11, pp.112~ (2019)
- Rogawski, D. S., "H3K36 methyltransferases as cancer drug targets : rationale and perspectives for inhibitor development", Future Med. Chem, 8, pp.1589~1607 (2016)
- Lee, J., "The promise and peril of chemical probe negative controls", ACS Chem. Biol, 16, pp.579~585 (2021)
- Nguyen, H., "LLY-507, a cell-active, potent, and selective inhibitor of protein-lysine methyltransferase SMYD2", J. Biol. Chem, 290, pp.13641~13653 (2015)
- Tie, J., "MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor", PLoS Genet, 6, pp.e1000879~ (2010)
- Jayachandran, J., "Molecular mechanism involved in epithelial to mesenchymal transition", Arch. Biochem. Biophys, 710, pp.108984~ (2021)
- Cheng, J., "A role for H3K4 monomethylation in gene repression and partitioning of chromatin readers", Mol. Cell, 53, pp.979~992 (2014)
- Franko, J., "Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy : an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System(ARCAD)database", Lancet Oncol, 17, pp.1709~1719 (2016)
- Wang, R., "The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer", BMC Cancer, 19, pp.1091~ (2019)
- Tong, X., "MYOCD and SMAD3", SMAD4 form a positive feedback loop and drive TGF-beta-induced epithelial-mesenchymal transition in non-small cell lung cancer, 2020, pp.39, 2890~2904